Friday, July 10, 2026

Drug profile · INN

cediranib maleate

cediranib maleate (ZEMFIRZA) is an FDA-listed pharmaceutical active ingredient.

EMA: application withdrawn Antineoplastic and immunomodulating agents (L01) L01XE32
Patents linked 0
Pipeline programs 3
News articles 0
Drug details — cediranib maleate
Class
Antineoplastic and immunomodulating agents (L01)
Route
Patents
0
Programs
3
Data quality
0.83

Quick answer

cediranib maleate (ZEMFIRZA) is an FDA-listed pharmaceutical active ingredient.

Key facts

INN cediranib maleate
Brand ZEMFIRZA
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01XE32

Approval history

Authority Status Date
EMA application withdrawn

Pipeline programs

  1. Cediranib Phase 3 · AstraZeneca · Colorectal Cancer
  2. Cediranib Phase 3 · AstraZeneca · Recurrent Glioblastoma
  3. Cediranib Phase 2 · United Therapeutics Europe · Alveolar Soft-part Sarcoma

Related & competitor drugs

  1. abiraterone acetate Antineoplastic and immunomodulating agents (L02)
  2. anagrelide Antineoplastic and immunomodulating agents (L01)
  3. apremilast Antineoplastic and immunomodulating agents (L04)
  4. arsenic trioxide Antineoplastic and immunomodulating agents (L01)
  5. axitinib Antineoplastic and immunomodulating agents (L01)
  6. azacitidine Antineoplastic and immunomodulating agents (L01)

Frequently asked questions

What is cediranib maleate?

cediranib maleate (ZEMFIRZA) is an FDA-listed pharmaceutical active ingredient.

What is the brand name for cediranib maleate?

ZEMFIRZA is a marketed brand name for cediranib maleate. Check FDA Drugs@FDA for the current US label holder and prescribing information.